代谢重编程:对抗癌药物耐药性的重要贡献者
Yunhan Zhu1,2,3, Weijie Yan1,2,3, Lingfeng Tong4
1Department of Ophthalmology Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China.
MedComm
|September 8, 2025
概括
癌细胞重新连接新陈代谢以促进生长和药物耐药性. 针对这些代谢变化,包括瘤微环境中的代谢变化,为克服对癌症疗法的耐药性提供了一个有希望的策略.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 代谢途径 代谢途径
背景情况:
- 癌细胞表现出代谢重编程,这是一个关键的标志,使得恶性行为如生长,入侵和迁移.
- 癌细胞的新陈代谢变化及其与瘤微环境 (TME) 的交叉声会对抗各种癌症疗法产生显著的抵抗力.
- 目前对代谢重编程如何驱动药物耐药性及其治疗向的理解仍然不完整.
研究的目的:
- 审查了解导致抗癌药物耐药性的瘤内在和TME相关代谢变化的最新进展.
- 探索驱动这些代谢变化的上游调节机制,重点关注葡萄糖,脂质和氨基酸代谢.
- 讨论治疗策略,特别是小分子抑制剂,以准癌症代谢以克服药物耐药性.
主要方法:
- 关于癌症代谢和耐药性的最新科学出版物的文献综述.
- 对癌细胞和瘤微环境 (TME) 中代谢重编程的分析.
- 专注于关键的代谢途径,包括葡萄糖,脂质和氨基酸代谢.
主要成果:
- 代谢重编程维持癌细胞的生长和入侵,并积极促进抗化学疗法,向疗法和免疫疗法的耐药性.
- 癌细胞和TME之间的异常代谢交叉声会给药物有效性带来障碍.
- 上游调节机制驱动代谢变化对于理解耐药性至关重要.
结论:
- 代谢重编程是抗癌药物耐药性的发展的一个关键因素.
- 针对癌症新陈代谢,无论是内在还是TME内,都是一个有前途的治疗途径.
- 针对癌症代谢的小分子抑制剂显示出克服药物耐药性的潜力.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Adaptive Mechanisms in Cancer Cells
7.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.0K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Cancer Stem Cells and Tumor Maintenance
5.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.9K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K


